Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Statistics Bedeviled Cymbalta Fibromyalgia NDA, Derail Chronic Pain Claim

Executive Summary

The statistical dispute behind Lilly's withdrawal of its chronic pain sNDA for Cymbalta should come as no surprise to the sponsor - the issue was previewed during FDA's review of an earlier duloxetine indication, fibromyalgia

You may also be interested in...



Industry, FDA Face Changes In Handling Of Missing Clinical Trial Data

A new National Academy of Sciences' report on missing clinical trial data is expected to lead to significant changes in how industry sponsors design and conduct studies and statistically account for the effects of drop-outs

Industry, FDA Face Changes In Handling Of Missing Clinical Trial Data

A new National Academy of Sciences' report on missing clinical trial data is expected to lead to significant changes in how industry sponsors design and conduct studies and statistically account for the effects of drop-outs

Cymbalta Advisory Committee Review In Chronic Pain Now Set For August

Rescheduled panel meeting could include discussion of statistical methods for dealing with missing patient data and safe use in a significantly broader population.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS050426

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel